How GLP-1 Receptor Agonists Evolved from Diabetes Treatments to Weight Loss Treatments

Peptidic GLP-1R agonists have received significant media coverage over the past year for their astounding efficacy in several indications. GLP-1R agonists now appear to be efficacious in reducing heart disease risk and in treating certain chronic kidney diseases, expanding their likely future use. Recently, we highlighted two small molecule leaders in the GLP-1R agonism space, orforglipron and danuglipron. This review by Oliver Philps provides an overview of GLP-1 agonists and where they fit in the treatment of diabetes, how the peptide drugs evolved over time to today’s weight loss medications, and what to expect next...